RxDoctor Payments Data

Anya Turetsky, MD

Neurology · Fort Myers, FLNPI 1497040315

Payments from drug & device makers

$1,608in general payments, 2019–2025

Across 66 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$159
  • UCB, Inc.$150
  • Novartis$123
  • Eisai Inc.$121
  • Acorda Therapeutics, Inc$113
  • Sanofi$100
  • plus $843 from 16 others

What the payments were for

  • Speaking & faculty fees$1137%
  • Food & beverage$1,44290%
  • Education$543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,608 in reported general payments places this provider in the 40th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$5,567
Medicare patients
50
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm43$35,580
Nurtec OdtRimegepant Sulfate24$34,516
Aimovig AutoinjectorErenumab-Aooe31$34,215
QuliptaAtogepant12$14,882
Levetiracetam65$1,331
Memantine Hcl33$621
ClopidogrelClopidogrel Bisulfate32$494
Duloxetine Hcl30$488
Gabapentin56$422
Donepezil Hcl48$410
Propranolol Hcl30$369
Carbidopa-LevodopaCarbidopa/Levodopa28$315
Sumatriptan Succinate29$302
Nortriptyline Hcl32$298
Verapamil ErVerapamil Hcl16$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$66$14,88212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →